The Biotech Brief
We quickly breakdown the latest news in biotech. Fast Facts. Big Breakthroughs.
Episodes
The Rare Pediatric Disease Priority Review Voucher (PPRV) program has been one of the few market-based incentives pushing biotech companies to develop treatments for children with rare conditions. But when its authorization lapsed in late 2024, the future of dozens of pediatric research programs was suddenly thrown into question. In this episode of The Biotech Brief, we walk through what the PPRV program is, how it has helped incen...
NIH grant cuts have halted hundreds of clinical trials—and now the agency has released a notice confirming delays and gaps in SBIR and STTR funding. In this episode of The Biotech Brief, we connect the dots between shrinking federal support, a stalled biotech innovation pipeline, and the growing pressure on startups and academic researchers alike. What does this mean for drug development timelines, investor confidence, and patient ...
Sanofi has officially ended its Phase III trial for a respiratory syncytial virus (RSV) vaccine targeting toddlers—citing futility as the reason for halting development. In this episode of The Biotech Brief, we unpack what happened and why it matters. From the biology of RSV and the unique challenges of vaccinating toddlers, to the competitive market landscape and strategic risks for pharma companies, we take you behind the headlin...
Gilead’s twice-yearly injectable PrEP, Yeztugo was recently approved by the FDA, but the story doesn’t end there. In this episode of The Biotech Brief, we explore how Gilead is leveraging global partnerships, generics, and regulatory streamlining to deliver Yeztugo to low- and middle-income countries without delay. Building on Episode 1, “Changing the Game in HIV Prevention,” this follow-up digs into what equitable access really ta...
Southwest Airlines is taking generic drugmakers to court and accusing more than 20 companies of price fixing that inflated costs for millions of Americans, including its own employees. In this episode of The Biotech Brief, we unpack the lawsuit, the history of generic drug cartel behavior, and why drug developers (yes, even biotech innovators) should be paying close attention. This episode explores how drug pricing moves from board...
Ocular Therapeutix is rebranding and repositioning. This episode of The Biotech Brief breaks down their plans for competing in the Wet AMD space, the company’s brand pivot to be more retina focused, and why this branding shift is more strategic than cosmetic.
Novartis’ blockbuster Cosentyx has hit a wall. In this episode of The Biotech Brief, we unpack the Phase 3 GCAptAIN trial results, where Cosentyx failed to show benefit for patients with giant cell arteritis. We explore what GCA is, why this label expansion mattered, and how the drug—once seen as a contender in this space—fell short. Plus, we look at the commercial implications, the competitive IL-6 landscape, and what this means f...
Regeneron has officially entered the multiple myeloma arena with FDA approval of Lynozyfic, a BCMA-targeted bispecific antibody for patients who’ve exhausted standard therapies. In this episode, we break down what Lynozyfic is, how it works, and how it stacks up against competitors.
In the first episode of The Biotech Brief, we break down what Yeztugo is, why it matters, how it compares to daily pills, and what this means for the $45 billion HIV prevention market.
Popular Podcasts
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com
The Clay Travis and Buck Sexton Show. Clay Travis and Buck Sexton tackle the biggest stories in news, politics and current events with intelligence and humor. From the border crisis, to the madness of cancel culture and far-left missteps, Clay and Buck guide listeners through the latest headlines and hot topics with fun and entertaining conversations and opinions.
Does hearing about a true crime case always leave you scouring the internet for the truth behind the story? Dive into your next mystery with Crime Junkie. Every Monday, join your host Ashley Flowers as she unravels all the details of infamous and underreported true crime cases with her best friend Brit Prawat. From cold cases to missing persons and heroes in our community who seek justice, Crime Junkie is your destination for theories and stories you won’t hear anywhere else. Whether you're a seasoned true crime enthusiast or new to the genre, you'll find yourself on the edge of your seat awaiting a new episode every Monday. If you can never get enough true crime... Congratulations, you’ve found your people. Follow to join a community of Crime Junkies! Crime Junkie is presented by Audiochuck Media Company.
DISGRACELAND is an award-winning music and true crime podcast about musicians getting away with murder and behaving very badly. Jerry Lee Lewis's 5th wife? Dead. Sid and Nancy? Both dead. Why? Because musicians are insane, and insane things happen to them. Why did we lose Amy Winehouse at 27? Was Debbie Harry really abducted by Ted Bundy as she claims? Is Patti Smith not just the "Godmother of Punk", but also the "Original True Crime Girl"? What really happened the night of the Jay Z nightclub stabbing? What do the Diddy indictments truly reveal? All these stories and more, on artists from every genre and their true crimes, in our massive 260-plus story archive. The Dead, the Stones, Johnny, Willie, Frank, Kurt, Courtney, Gaga, Lana, Taylor, and too many to name. DISGRACELAND is music history come to life through audio storytelling as you've never heard it before, with revealing facts: yes, assassins are the real reason the Beatles quit touring—reclaimed myths: no, Mama Cass didn't die from choking on a ham sandwich––and constant reckoning between art and artist––all told through the lens of true crime. This is the podcast for the self-proclaimed "Disgos", the musically obsessed and the true crime heads; the outsiders, the independent thinkers who know that the best history is the history that gets buried. DISGRACELAND is where host Jake Brennan tells the stories they didn't want told. The kind you'll end up telling someone else. Get ready to uncover hidden truths and buckle up for truly edge-of-your-seat storytelling. New, fully scripted, sound-designed episodes are released every Tuesday. Bonus chat-style episodes where Jake responds to voicemails, texts, and emails from Disgos hit on Thursdays, and "Rewind" episodes from our archive drop on Sundays. DISGRACELAND is not a journalistic podcast. It's an entertainment podcast inspired by true events. Certain dialogue and scenes are dramatized, as is common in scripted entertainment based on real stories. Sources and credits for each episode are available at www.disgracelandpod.com. To unlock ad-free listening, exclusive content, and connect with your fellow Disgos, go to www.disgracelandpod.com to become an All Access member. Rocka Rolla.